IADR Abstract Archives
Can Salivary Cytokines Predict Gastrointestinal Constipation and Quality of Life in Cerebral Palsy Subjects?
Objectives: The aim of this study was to investigate predictive factors in saliva for gastrointestinal (GI) constipation and quality of life (QOL) of individuals with cerebral palsy (CP).
Methods: We recruited a total of 63 subjects aging from 5-17 years with spastic CP who received physical rehabilitation. Subjects were assigned into 4 groups that were assigned as CP with constipation (G1), CP without constipation (G2), and controls without CP with constipation (G3) and without CP and without constipation (G4). Subjects’ demographics, use of antiepileptic drugs (AEDs), motor function, caregiver priorities and child health index of life with disabilities (CPCHILD) were included. In addition to medical metadata, a subset of subjects was evaluated for oral and systemic inflammation through gingival bleeding and serum cytokine levels (TNF-α, IL-1β, IL-6, IL-8, IL-10) respectively. Statistical significance was evaluated by ANOVA One-Way (parametric data) and Kruskal Wallis (non-parametric data).
Results: IL-1 and IL-6 were mostly associated with constipation and lower quality of life. In addition, a significant relationship was found between the type of medication and constipation. Subjects taking GABA and GABA+ (GABA in association with other medication) were more likely to be constipated than the other groups (P < 0.01). Additionally, quality of life was directly correlated with constipation; subjects in G1 presented the lower mean score of CPCHILD (49.0 ±13.1) compared to G2 (71.5 ± 16.7), when compared to G3 (88.9 ± 7.5), and G4 (95.5 ±5.0) (P < 0.01). Inflammation was more severe for subjects in G1 (P < 0.001). There were no differences among groups regarding gender (P = 0.332) and age (P = 0.292).
Conclusions: Overall, our results suggest that GI constipation could be monitored by salivary cytokines and new findings such as type of medication have been correlated with CP quality of life, which may predict dysbiosis.
Methods: We recruited a total of 63 subjects aging from 5-17 years with spastic CP who received physical rehabilitation. Subjects were assigned into 4 groups that were assigned as CP with constipation (G1), CP without constipation (G2), and controls without CP with constipation (G3) and without CP and without constipation (G4). Subjects’ demographics, use of antiepileptic drugs (AEDs), motor function, caregiver priorities and child health index of life with disabilities (CPCHILD) were included. In addition to medical metadata, a subset of subjects was evaluated for oral and systemic inflammation through gingival bleeding and serum cytokine levels (TNF-α, IL-1β, IL-6, IL-8, IL-10) respectively. Statistical significance was evaluated by ANOVA One-Way (parametric data) and Kruskal Wallis (non-parametric data).
Results: IL-1 and IL-6 were mostly associated with constipation and lower quality of life. In addition, a significant relationship was found between the type of medication and constipation. Subjects taking GABA and GABA+ (GABA in association with other medication) were more likely to be constipated than the other groups (P < 0.01). Additionally, quality of life was directly correlated with constipation; subjects in G1 presented the lower mean score of CPCHILD (49.0 ±13.1) compared to G2 (71.5 ± 16.7), when compared to G3 (88.9 ± 7.5), and G4 (95.5 ±5.0) (P < 0.01). Inflammation was more severe for subjects in G1 (P < 0.001). There were no differences among groups regarding gender (P = 0.332) and age (P = 0.292).
Conclusions: Overall, our results suggest that GI constipation could be monitored by salivary cytokines and new findings such as type of medication have been correlated with CP quality of life, which may predict dysbiosis.
